This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kola, B. Articles by Korbonits, M. Search for Related Content PubMed PubMed Citation Articles by Kola, B. Articles by Korbonits, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cushing's Syndrome Obesity Hazardous Substances DB HYDROCORTISONE Related Collections Adrenal and Hypertension Metabolism Obesity

Changes in Adenosine 5'-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing’s Syndrome

Centre for Endocrinology (B.K., M.C.-C., F.L., A.B.G., M.K.), Barts and the London School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom; and Department of Internal Medicine (G.A., G.G., M.B.), University of Ancona 60100, Italy

Address all correspondence and requests for reprints to: Márta Korbonits, M.D., Ph.D., Professor of Endocrinology and Metabolism, Centre for Endocrinology, John Vane Science Centre, Barts and the London School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom. E-mail: m.korbonits{at}qmul.ac.uk.

Objective: Features of the metabolic syndrome such as central obesity with insulin resistance and dyslipidemia are typical signs of Cushing’s syndrome and common side effects of prolonged glucocorticoid treatment. AMP-activated protein kinase (AMPK), a key regulatory enzyme of lipid and carbohydrate metabolism as well as appetite, is involved in the development of the deleterious metabolic effects of excess glucocorticoids, but no data are available in humans. In the current study, we demonstrate the effect of high glucocorticoid levels on AMPK activity of human adipose tissue samples from patients with Cushing’s syndrome.

Methods: AMPK activity and mRNA expression of genes involved in lipid metabolism were assessed in visceral adipose tissue removed at abdominal surgery of 11 patients with Cushing’s syndrome, nine sex-, age-, and weight-matched patients with adrenal incidentalomas, and in visceral adipose tissue from four patients with non-endocrine-related abdominal surgery.

Results: The patients with Cushing’s syndrome exhibited a 70% lower AMPK activity in visceral adipose tissue as compared with both incidentalomas and control patients (P = 0.007 and P < 0.001, respectively). Downstream targets of AMPK fatty acid synthase and phosphoenol-pyruvate carboxykinase were up-regulated in patients with Cushing’s syndrome. AMPK activity was inversely correlated with 0900 h serum cortisol and with urinary free cortisol.

Conclusions: Our data suggest that glucocorticoids inhibit AMPK activity in adipose tissue, suggesting a novel mechanism to explain the deposition of visceral adipose tissue and the consequent central obesity observed in patients with iatrogenic or endogenous Cushing’s syndrome.

This article has been cited by other articles:

				M.-J. Barahona, N. Sucunza, E. Resmini, J.-M. Fernandez-Real, W. Ricart, J.-M. Moreno-Navarrete, T. Puig, J. Farrerons, and S. M. Webb Persistent Body Fat Mass and Inflammatory Marker Increases after Long-Term Cure of Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3365 - 3371. [Abstract] [Full Text] [PDF]

				S. Bao, V. J. Briscoe, D. B. Tate, and S. N. Davis Effects of Differing Antecedent Increases of Plasma Cortisol on Counterregulatory Responses During Subsequent Exercise in Type 1 Diabetes Diabetes, September 1, 2009; 58(9): 2100 - 2108. [Abstract] [Full Text] [PDF]